My Passport
News and Commentary education Live Coronavirus Dashboard
S&P 500 ETF
0.00%
NASDAQ ETF
0.00%
Dow Jones ETF
0.00%


IBM Partners With Google Cloud To Scale Enter...
Amazon Defies Tech Slump, Launching Next-Gen...
Honeywell Expects Uneven Earnings Progression...
The Market Is Undervaluing Microsoft, Says An...
Pinterest Rallies On $4 Billion AWS AI Invest...
Elon Musk Sets SPCX Price At $135 A Share—And...
Costco's E-Commerce Momentum Shows No Signs O...
Palantir Expands Google Cloud AI Partnership
The Rise of the Solo General Partner Investor

While modern day venture capital originated in the 1940s, the very first iteration of venture capital (VC) investments--where a general partner (GP) investments capital on behalf of a limited partner (LP)--dates all the way back to the early 1600s with the founding of East India...

  • How are Higher Rates Impacting the Housi...
  • Quantitative Tightening: How the Fed Co...
  • Should Investors Worry About Inflation?
  • How Semiconductors are Made and Why its...
  • What Are NFTs?
    • Inflation: What is it and How to Protect From...
    Short Squeezes Could Lead to Market Dislocati...
    How Google and Facebook Antitrust Lawsuits Co...
    Vaccine News Triggers Growth to Value Rotatio...
    Energy
    Materials
    Industrial
    Finance
    Consumer D...
    Consumer S...
    Informatio...
    Telecommun...
    Health Car...
    Utilities
    Oil
    Gold
    ETFs IPOs Ratings
     
    S&P 500 ETF
    0.00%
    NASDAQ ETF
    0.00%
    Dow Jones ETF
    0.00%
    Search
    News and Commentary
    Education
    Market
    ETFs
    IPOs
    Ratings
    Newsfeed
    My passport
    Login
    Sign up

    GILEAD SCIENCES INC (NASDAQ: GILD)

    Overview
    current price
    $129.16
    $129.16
    change
    -0.02 | -0.02%
    -0.02 | -0.02%
    Yesterday's Close
    129.18
    open
    130.09
    volume
    15.37 M
    30d. avg volume.
    6.78 M
    1 day
    128.92 - 131.66
    52 weeks
    104.46 - 157.29
    p/e
    17.57
    beta
    0.3159
    market cap
    160.36 B
    dividend yield
    2.54%
    Industry
    -
    GILD by TradingView
    News and Commentary
    Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles While September remains the most seasonally treacherous month for U.S. stocks, a select group of S&P 500 companies has bucked the bearish trend, delivering consistent gains even...
    CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans CVS Health Inc. (CVS&nb...
    44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Sto... Time Magazine's annual 100 Most Influential Companies list for 2025 includes many companies investors are familiar with, with numerous names originating from the growing artifici...
    FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $2... During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s
    Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline U.S. President Donald Trump, on Tuesday, disclosed plans for a "major tariff" on foreign pharmaceuticals."We're going to be announcing very shortly a ma...
    Best And Worst Performing S&P 500 Stocks Since Trump's Election Win Financial markets have been volatile since President Donald Trump's election on Nov. 5, 2024, and subsequent inauguration. Which companies have surged under the new administratio...
    Market Update: Dow Rises 100 Points as Powell Continues Cautious Tone on Interest Rates Stocks were little changed Tuesday as market participants reacted to a cautious tone on interest rates from Federal Reserve Chair Jerome Powell. The Dow Jones Industrial Average...
    Market Update: Dow Falls 700 Points on Hot December Jobs Report Stocks fell on Friday as December's red hot jobs report dashed investor expectations for more interest rate cuts this year. The Dow Jones Industrial Average dropped nearly 700 po...
    Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing... Thursday, Gilead Sciences, Inc. (
    Market Update: Dow Climbs 200 Points on Another In-Line Inflation Report Stocks rose Thursday as investors continued to buy the dip in tech stocks ahead of the Federal Reserve's policy meeting next week. The Dow Jones Industrial Average rose over 200...
    StockTwits
    StockTwits
    Most Shared
    Starbucks Stock Holds Steady As Investors Digest Extensive Corporate Restructuring Plan
    IBM Is Chasing A '$1 Trillion Value Creation Engine' — And It's Spending $15 Billion To Get There
    Consumers Are Feeling The Squeeze — And That Could Be Walmart's Biggest Advantage
    Most Popular
    SanDisk And Micron Had Their Run – This New 'Photonics' ETF Has 15 Triple-Digit Gainers Inside
    Space Earnings Heat Up: Rocket Lab Tops $200M, Firefly Hits Record Revenue, Redwire Backlog Surges
    Meta's $125 Billion AI Bet Might Be The Capex Trap Of The Decade
    popular tags
    Earnings
    Apple
    Amazon
    Coronavirus
    Coronavirus Impact
    Tesla
    Google
    China
    Covid-19
    mobile iOS
    social Facebook Twitter Youtube Linkedin Rss Google News
    Passport to Wall Street About Us Contact Advertise Privacy Policy Terms of Service
    Sign Up
    © 2026 Passport to Wall Street
    Quotes are at least 20 minutes delayed

    Join now and unlock premium features

    Already Have An Account?